Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Progressive Metastatic Prostate Cancer”

87 trials

Showing 20 of 87 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06004661
What this trial is testing

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 23
Not applicableStudy completedNCT00002981
What this trial is testing

PET Scan in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 173
Testing effectiveness (Phase 2)Study completedNCT00390468
What this trial is testing

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

Who this might be right for
Metastatic CancerPainProstate Cancer
National Cancer Institute (NCI) 18
Testing effectiveness (Phase 2)Study completedNCT02814968
What this trial is testing

PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide

Who this might be right for
Prostate Cancer Metastatic
The European Uro-Oncology Group 66
Testing effectiveness (Phase 2)Ended earlyNCT01732549
What this trial is testing

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer
Ipsen 144
Large-scale testing (Phase 3)Active Not RecruitingNCT06691984
What this trial is testing

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Amgen 707
Large-scale testing (Phase 3)Not Yet RecruitingNCT07795268
What this trial is testing

Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
Norroy Bioscience Co., LTD 600
Post-approval studies (Phase 4)Study completedNCT02116582
What this trial is testing

Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Astellas Pharma Europe B.V. 215
Early research (Phase 1)Study completedNCT01414283
What this trial is testing

Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

Who this might be right for
Prostate Cancer
Progenics Pharmaceuticals, Inc. 52
Testing effectiveness (Phase 2)Study completedNCT05114746
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 94
Not applicableStudy completedNCT04281147
What this trial is testing

Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body

Who this might be right for
Prostate Cancer
Bayer 4,301
Testing effectiveness (Phase 2)Study completedNCT02225704
What this trial is testing

Radium-223 in Combination With Enzalutamide

Who this might be right for
Prostate Cancer
Cancer Trials Ireland 45
Testing effectiveness (Phase 2)Ended earlyNCT03531827
What this trial is testing

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Who this might be right for
Metastatic Castration Resistant Prostate CancerProstate Neoplasms
National Cancer Institute (NCI) 4
Testing effectiveness (Phase 2)Study completedNCT05670106
What this trial is testing

Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 62
Testing effectiveness (Phase 2)Study completedNCT00081172
What this trial is testing

Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00005848
What this trial is testing

R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
Fox Chase Cancer Center 7
Early research (Phase 1)Ended earlyNCT05124795
What this trial is testing

IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Immunic AG 18
Testing effectiveness (Phase 2)Looking for participantsNCT07206056
What this trial is testing

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Who this might be right for
Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals 188
Testing effectiveness (Phase 2)Ended earlyNCT00670046
What this trial is testing

Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 15
Testing effectiveness (Phase 2)Study completedNCT01091103
What this trial is testing

Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

Who this might be right for
Metastatic Progressive Castration-resistant Prostate Cancer
Pfizer 60
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation